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ABSTRACT
The probiotic and technological potentials of lactic acid bacteria originating from human milk are
becoming a remarkable research area. In the present study, Limosilactobacillus vaginalis MA-10 isolated
from human milk was investigated in vitro for its probiotic and technological aspects. According to the
results obtained in the study, MA-10 strain exhibited non-haemolytic activity and various degrees of
sensitivity to most of the tested antibiotics. The strain showed good resistance to the gastrointestinal system
and maintained its viability under these conditions. Its antimicrobial activity against human or clinical
bacterial and fungal microorganisms and fish bacteria was determined in the range of 2.38–11.22 mm. The
MA-10 strain was able to assimilate cholesterol ranging from 31.42 to 82.30%. The strain showed 9.34%
ferrous-ion chelating and 32% DPPH free radical scavenging activities. These initial results from the
present study confirm that L. vaginalis MA-10 may be a new source with appropriated probiotic and
technological traits for various industries, and further in vivo assays.Due to the limited number of studies
on L. vaginalis strains originated from human breast milk in the literature, the data obtained in this study
are thought to be important for revealing the basic probiotic properties of the strain.
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1. INTRODUCTION
A healthy gastrointestinal tract microbiota is highly balanced in terms of the distribution of
beneficial/harmful microorganisms, but the deterioration of this balance may lead to the onset of
a pathological process called microbial dysbiosis and the development of symptoms related to it.
The deterioration of commensal microbiota homeostasis causes a wide range of diseases. Most
of the bacterial groups, such as Lactobacillus, Lactococcus, Bacillus, Bifidobacterium, which are
naturally found in the gastrointestinal tract, are frequently used as food and health-promoting
supplements to re-establish homeostasis (Kothari et al., 2019). Also, in recent years, human milk
has gained considerable importance as safe and attractive source of probiotic lactic acid bacteria
(LAB). The most commonly found and isolated bacteria species from human breast milk include
Lactobacillus, Bifidobacterium, Streptococcus, and Enterococcus. Human milk bacteria are
gaining much attention because of their ability to protect the host from pathogenic microor-
ganisms, survive in the gastrointestinal tract, adhere to epithelial cells of the mucosa, assimilate
cholesterol, support immune defence, produce antimicrobial substances and mediators (Amenu,
2014).
The use of LAB in food and feed industrial applications enjoys a “generally recognised as
safe” (GRAS) status. Literature have focused on the Lactobacillus genus among LAB, and their
probiotic effects were reported to be genus-specific, species-specific, or even strain-specific. In
the literature, the research is generally focused on the probiotic potential of Lactobacillus gasseri,
Lactobacillus fermentum, and Lactobacillus plantarum strains originated from human milk
(Gunyakti and Asan-Ozusaglam, 2018, 2019). However, few studies have reported the probiotic
potential and technological properties of Limosilactobacillus vaginalis isolated from human
stomach, feces, vagina, and chicken. Therefore, the aim of the current study was to investigate
L. vaginalis originated from human milk as a possibly potential probiotic candidate.
2. MATERIALS AND METHODS
2.1. Identification of Lactobacillus strains
The Gram-positive and catalase-negative isolate with bacillus morphology was first identified
using API 50 CHL (BiomerieuxSA, France) according to the manufacturer’s instructions. The
defined strain was then sent to IONTEK (Turkey) for molecular identification by 16S rRNA
PCR analysis.
2.2. Determination of safety
Haemolytic activity was verified by inoculating Colombia agar media containing 5% sheep blood
(OR-BAK, Turkey) with the isolate and incubating under anaerobic condition at 37 8C for 24 h.
Haemolytic activity was determined by zone formation around the colonies. The greenish zone
was considered a-haemolysis, clear zone was classified as b-haemolysis, and no zone indicated
g-haemolysis.
The susceptibility profiles of L. vaginalis MA-10 were assessed by the disc diffusion method
against eleven commercial antibiotics (Oxoid, Germany). The suspension adjusted to Mc Far-
land 0.5 densities was spread on MRS agar medium. Each antibiotic disc was located on the
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inoculated MRS agar medium in triplicate, and the Petri dishes were incubated at 37 8C for 24 h.
The inhibition zone diameters were measured and assessed as stated by CLSI (Clinical and
Laboratory Standards Institute) guideline (Sharma et al., 2016).
2.3. Determination of probiotic potential and technological properties
2.3.1. Cell viability under simulated gastrointestinal conditions. The resistance of L. vaginalis
MA-10 to simulated gastric conditions including low pH, bile, gastric, and small intestine juice
tolerances were determined as described in our previous study (Gunyakti and Asan-Ozusaglam,
2019).
2.3.2. Determination of antimicrobial activity. Fifteen clinical and food-borne bacteria, two
fungal strains and seven fish originated pathogenic bacteria were used to determine the anti-
microbial activity of L. vaginalis MA-10 using well diffusion method. The indicator microor-
ganisms adjusted to McFarland 0.5 standard were spread onto the specific agar media. MA-10
strain supernatant (100 mL) was placed into each well (7 mm diameter). The plates were
incubated for 24 h and then the inhibition zones around the wells were measured using Vernier
caliper. The inhibition zone diameter was obtained by subtracting the diameter of the well from
the entire inhibition diameter. The experiment was conducted three times.
2.3.3. Cholesterol assimilation activity. L. vaginalis MA-10 culture was inoculated into the
MRS broth containing 100 mg mL1 of cholesterol (Sigma-Aldrich, USA) and different con-
centrations of bile (0.3 and 1%) (Oxoid, UK) then incubated at 37 8C for 24 h. The cholesterol
assimilation of supernatant and pellet was separately evaluated using the o-phthalaldehyde
method (Hosono et al., 1999). Cholesterol removal ability of MA-10 was calculated as described
in our previous study (Gunyakti and Asan-Ozusaglam, 2019).
2.3.4. Antioxidant activity. The free radical scavenging activity and ferrous-ion chelating
property of MA-10 strain were measured using 2,2-diphenyl-1-picrylhydrazyl (DPPH) as
described in our previous study (Gunyakti and Asan-Ozusaglam, 2019).
2.4. Statistical analysis
Statistical analysis was performed with the Mann-Whitney U-test to identify significant dif-
ferences in antibiotic susceptibility and antimicrobial activity assay results. The differences were
considered significant at a P-value of <0.05. The statistical analyses were conducted using SPSS
version 22 (SPSS Inc, Chicago, IL, USA).
3. RESULTS AND DISCUSSION
3.1. Identification of Lactobacillus strain
The isolated strain was identified by API 50 CHL System as Lactobacillus acidophilus (98.7%).
Genotypic identification according to the 16S rRNA sequences showed that MA-10 strain was
L. vaginalis. However, molecular identification with 16S rRNA of strains may be more consistent
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than microbial and biochemical techniques. Therefore, the strain was identified as L. vaginalis
MA-10 according to the 16S rRNA PCR analysis results.
3.2. Determination of safety
The strain had no-zones around the colonies on the blood agar. L. vaginalis MA-10 exhibited g-
haemolytic or non-haemolytic activity. Haemolytic activity is related to virulence factors that
can be found in pathogenic microorganisms, so the microorganisms under investigation for
probiotic properties are expected to be non-haemolytic strains (FAO/WHO, 2002). In this study,
the absence of a lysis region for MA-10 strain indicates the safety of this strain as a probable
probiotic candidate in food and other application areas.
L. vaginalis MA-10 showed susceptibility to chloramphenicol, amoxicillin, erythromycin,
and ampicillin and resistance to amikacin, gentamicin, kanamycin, nalidixic acid, and
ofloxacin (Table 1). The intermediate resistance was determined against cloxacillin and
penicillin G. There are mean differences in the antibiotic susceptibility of MA-10 strain
against the tested antibiotics. The statistical analysis, however, indicated that the inhibition
zone averages of MA-10 strain were not statistically significant atthe significance level of
0.05 (P > 0.05). The safety concerns related to the use of antibiotic-resistant strains as
probiotics are due to the possibility of transferring antibiotic-resistance genes to pathogens in
the intestine (Curragh and Collins, 1992). However, in the literature, the antibiotic resistance
of some LAB is thought to be natural or intrinsic, so chromosomally encoded and thereby
non-transmissible. For example, Bifidobacterium strains resistant to various antibiotics in
quinolone and aminoglycoside groups are used as starter cultures in food applications.
Resistance to aminoglycoside antibiotics, such as amikacin, kanamycin, streptomycin, andg-
entamicin, is considered to be intrinsic in the Lactobacillus genus. The reason for the resis-
tance is the lack of electron transport mediated by the cytochrome, as it mediates the drug
uptake (Danielsen and Wind, 2003). Literature information supports our study data, sug-
gesting that L. vaginalis strain resistance genes are structural and the risk of transfer to
other microorganisms is low. However, in later studies, these results can be confirmed by
molecular-based methods.
3.3. Determination of probiotic potential and technological properties
3.3.1. Cell viability under simulated gastrointestinal conditions. The high tolerance to
acidity at pH 2 and 3 was found for MA-10 with a high survival rate after 3 h (Table 2). The
survival rate was found to be over 100% for both bile concentrations during the incubation
period (4 h) (Table 2). During fasting and after the meal, the pH ranges from 1.5 to 4.5, and
the food digestion is completed in about 3 h (Lebeer et al., 2008). MA-10 strain showed
high survival rates at pH 3. Delgado et al. (2015) reported almost similar growth rate for two L.
vaginalis strains (LV121 and LV51) from the human stomach. Herein, MA-10 strain exhibited
cell viability as 7.26 and 7.65 CFU mL1 at pH 2 and 3, respectively, after 3 h. MA-10 strain
showed higher viability at pH 2. The strains that pass the acidic barrier of the stomach are then
exposed to bile fluid. Therefore, tolerance to bile is another criterion to be a good probiotic.
The strain has maintained its viability under different pH and bile conditions.
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Table 1. Antibiotic susceptibility profile of L. vaginalis MA-10
Antibiotics
AK AMC AM C OB E CN K NA OFX P
Inhibition zone
diameter (mm)
7.38b ± 0.26 26.11 ± 0.91 26.58 ± 1.04 25.31 ± 0.93 19.86 ± 0.86 26.08 ± 1.36 7.66 ± 0.61 – – – 19.68 ± 1.56
CLSIa R S S S IR S R R R R IR
– Indicates no inhibition zone.
aThe inhibition zones was evaluated as Susceptible (S) > 20, Intermediate (IR) ≅ 15–19, Resistant (R) ≤ 14.
bDiameter of the inhibition zone including disc diameter. AK: Amikacin (10 mg); AMC: Amoxicillin (30 mg); AM: Ampicillin (10 mg);
C: Chloramphenicol (10 mg); OB: Cloxacillin (5 mg); E: Erythromycin (15 mg); CN: Gentamicin (10 mg); K: Kanamycin (30 mg); NA: Nalidixic Acid









L. vaginalis MA-10 also showed good survival ability under simulated gastric and pancreatic
conditions (Table 3). In general, most LAB seem to have natural survival ability in pancreatin,
but contrary to pancreatin tolerance, bile tolerance is specific to the strain (Masco et al., 2007).
L. vaginalis MA-10 showed 100.69% survival rate after 3 h under simulated gastric juice con-
ditions at pH 2 and 3. The results indicate that MA-10 can survive under gastrointestinal
conditions and can thus be a probable candidate as probiotic strain.
3.3.2. Antimicrobial activity. Antimicrobial activities of MA-10 tested against 25 indicator
strains are presented in Table 4. The inhibition zones of the food-borne and clinical bacterial
strains varied from 2.38 to 11.22 mm. The highest two inhibitory activities were found against
Staphylococcus epidermidis ATCC 11228 and Listeria monocytogenes ATCC 7644. The strain
inhibited the growth of two Candida strains and inhibition zone diameters were determined as
2.70 and 2.87 mm. The growth of all fish originated pathogenic bacteria was also inhibited by
MA-10 strain with inhibition zones ranging from 3.53 to 7.35 mm. The highest antibacterial
activity was determined against Aeromonas hydrophila. The statistical analysis indicated that the
differences between zone averages of MA-10 were not statistically significant at the significance
level of 0.05 (P > 0.05).
Anukam and Reid (2007) reported the antibacterial activity of vaginal L. vaginalis against
Escherichia coli O157:H7 and Staphylococcus aureus as over 15 mm of inhibition zone diameter.
In another study conducted by Siroli et al. (2017), vaginal L. vaginalis BC15, BC16, and BC17
showed antibacterial activities against L. monocytogenes ATCC 13932 with a 1 to 3 mm inhi-
bition zone diameter. Herein, MA-10 strain showed higher antibacterial activity than these
vaginal L. vaginalis strains against L. monocytogenes ATCC 7644 with 9.79 mm inhibition zone
diameter. Intestinal colonisation or infection of the intestine with pathogenic microorganisms
may cause a risk of necrotising enterocolitis that can be decreased with the colonisation with
lactobacilli and bifidobacteria of the intestine (Reid et al., 2003). The antimicrobial activities of













rate (%)0 h 3 h 0 h 3 h 0 h 3 h
10.35 10.54 101.83 9.95 9.57 96.18 10.02 10.09 100.69
Table 2. Acid and bile tolerance of L. vaginalis MA-10
Acid tolerance (log10 CFU mL
1) Bile tolerance (log10 CFU mL
1)
pH 2 pH 3 0.3% bile 1% bile
0 h 1 h 3 h
Survival
rate (%) 0 h 1 h 3 h
Survival
rate (%) 0 h 4 h
Survival
rate (%) 0 h 4 h
Survival
rate (%)
7.74 7.49 7.26 93.79 8.60 8.23 7.65 88.95 7.37 8.38 113.70 7.97 8.38 105.14
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probiotic strains are necessary to prevent infection or invasion of pathogenic microorganisms.
Various LAB are known to synthesize various inhibitory agents such as bacteriocins, organic
acids, but in this study, it was observed that the inhibitory activity was lost at neutral pH.
Therefore, the inhibitory activity in the current situation can be ascribed to organic acid-like
metabolic products from L. vaginalis MA-10. These results indicated that MA-10 strain can be
used as a feed supplement in aquaculture in the form of single or co-culture with various
probiotic microorganisms. Besides, the strain may be a new alternative bio-source that exhibits
inhibitory activity against human pathogens.
3.3.3. Cholesterol assimilation activity. The cholesterol-reducing activity of MA-10 was
determined in vitro in the presence of 0.3 and 1% bile, the results obtained were 44.69 and
31.42% for pellets and 82.30 and 81.19% for supernatants, respectively. The higher anti-
cholesterol activity at both bile concentrations was obtained for supernatants compared to
Table 4. Antimicrobial activity of L. vaginalis MA-10
Test microorganisms
L. vaginalis MA-10
Inhibition zone diameter (mm)
Human food borne and clinical
Bacterial strains
E. coli ATCC 11229 3.76 ± 0.08a
E. coli O157:H7 –
B. megaterium (Pasteur Ins. 5117) 3.52 ± 0.03
S. enteritidis RSKK 171 3.21 ± 0.16
B. cereus RSKK 863 3.25 ± 0.66
B. subtilis RSKK 244 –
E. coli ATCC 35218 –
M. luteus NRRL B-4375 –
S. enteritidis ATCC 13076 –
S. sonnei MU:57 2.38 ± 0.27
S. aureus ATCC 25923 –
Y. enterocolitica NCTC 11175 –
E. faecalis ATCC 29212 –
L. monocytogenes ATCC 7644 9.79 ± 1.13
S. epidermidis ATCC 11228 11.22 ± 0.76
Fungal strains
C. albicans ATCC 10231 2.70 ± 0
C. glabrata RSKK 04019 2.87 ± 0.24
Fish originated bacterial strains
V. alginolyticus 4.64 ± 0.57
V. anguillarium M1 3.73 ± 0.35
V. anguillarium A4 3.53 ± 0.31
A. hydrophila ATCC 19570 7.35 ± 0.78
L. garviae 4.44 ± 0.45
Y. ruckeri 4.88 ± 0.73
S. agalactiae Pas. Inst. 55118 4.71 ± 0.76
– Indicates no antimicrobial activity.
aDiameter of the inhibition zone including disc diameter.
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pellets. The increased bile concentrations caused a small decrease in cholesterol assimilation
activities of the pellet and supernatant. The possible cause of cholesterol assimilation activities of
Lactobacillus strains is to decrease the solubility of cholesterol and therefore reduce cholesterol
intake (Oh et al., 2018). The high serum cholesterol level can be a risk factor for cardiovascular
disease; therefore, cholesterol-reducing ability has become an important functional feature for
the selection of probiotic strains. There is no literature data on the cholesterol-lowering activity
of L. vaginalis according to our knowledge. Nowadays, the development of cholesterol-lowering
bio-therapeutics has become an important area. L. vaginalis MA-10 can assimilate with good
cholesterol-lowering percentages and, therefore, can be a new bio-agent to reduce cholesterol
level.
3.3.4. Antioxidant activity. The antioxidant activity was evaluated by DPPH free radical
scavenging and ferrous-ion chelating activities. The strain showed 32% DPPH free radical
scavenging and 9.34% ferrous-ion chelating activities. Many LAB have special systems to pre-
vent the organisms from the reactive oxygen species. The activities of various LAB to reduce
reactive oxygen species have been induced by many in vitro experiments. However, there are a
limited number of studies on L. vaginalis strains. Delgado et al. (2015) tested the total anti-
oxidant activity of L. vaginalis LV51 and LV121 strains and found 21% and no activity. Several
synthetic antioxidants widely used in food, cosmetic, and medicinal industries are carcinogenic
and may cause liver damage (Saduakhasova et al., 2013). Antioxidant activity of the probiotic
bacteria plays an important role in the protection of host health from free radicals. Therefore, L.
vaginalis MA-10 can be an alternative to the synthetic antioxidants as a natural antioxidant
source.
4. CONCLUSIONS
In the current study, probiotic potential and some technological properties of L. vaginalis MA-
10 isolated from human milk were examined in vitro. MA-10 strain exhibited appropriate
probiotic effects including non-haemolytic activity and high tolerance to gastrointestinal con-
ditions. The results of the antimicrobial, antioxidant, and anti-cholesterol activity assays also
indicated that MA-10 strain can beneficially affect host health with these properties. Considering
the results of the current study, L. vaginalis MA-10 strain may be a new bio-source for food,
feed, and pharmaceutical industries after confirming its benefits and safe use in animal models.
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